Petrelintide
Also referenced as: ZP8396
A long-acting amylin analogue investigated for obesity and metabolic disease.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Clinical Trials
Investigational; not FDA-approved for the uses discussed.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A long-acting amylin analogue investigated for obesity and metabolic disease.
Investigational; not FDA-approved for the uses discussed.
Sponsor topline results are not mature phase 3 evidence; claims of superior tolerability or muscle preservation need direct comparative studies.
Why It's Being Studied
- Obesity research
- Amylin signalling
Mechanism of Action
Amylin-receptor agonism targets satiety-related pathways, distinct from a GLP-1-only medicine.
Amylin-receptor agonism targets satiety-related pathways, distinct from a GLP-1-only medicine. Sponsor topline results are not mature phase 3 evidence; claims of superior tolerability or muscle preservation need direct comparative studies.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Obesity research
- Amylin signalling
- Subcutaneous clinical research
Evidence Summary
Phase 2 ZUPREME findings support weight-loss activity; the sponsor reported phase 3 initiation in September 2026.
Higher tiers carry more weight. Filled tiers have evidence for Petrelintide; tap to read it.
- Phase 2 ZUPREME findings support weight-loss activity; the sponsor reported phase 3 initiation in September 2026.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Phase 2 ZUPREME findings support weight-loss activity; the sponsor reported phase 3 initiation in September 2026.
Reported Adverse Events in Research
- Gastrointestinal effects and unresolved long-term safety require investigation.
Limitations of Current Evidence
- Sponsor topline results are not mature phase 3 evidence; claims of superior tolerability or muscle preservation need direct comparative studies.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Petrelintide | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Clinical Trials | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Petrelintide — regulatory document